摘要
原发纵隔大B细胞淋巴瘤(primary mediastinal large B-cell lymphoma,PMBL)是一种起源于纵隔的成熟侵袭性大B细胞淋巴瘤,具有独特的临床、病理及分子学特征。近年来,对PMBL发病机制的认识及治疗均有不同程度的更新,特别是新药治疗领域取得了较大进展。为提高我国临床医师对PMBL的诊断及治疗水平,中华医学会血液学分会淋巴细胞疾病学组和中国临床肿瘤学会(CSCO)淋巴瘤专家委员会组织相关专家组,制订了本共识。
Primary mediastinal large B-cell lymphoma(PMBL)is an aggressive B-cell lymphoma that is thought to arise from thymic(medullary)B cells and has unique clinicopathologic and molecular features.In recent years,the understanding of the pathogenesis and treatment of PMBL has been updated to varying degrees,particularly in the area of new drug therapy.In order to improve the diagnosis and treatment of PMBL in China,the Lymphocyte Disease Group of the Chinese Medical Association(CMA)and the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology(CSCO)commissioned a group of experts to formulate this consensus.
作者
中华医学会血液学分会淋巴细胞疾病学组
中华医学会血液学分会淋巴细胞疾病学组中国临床肿瘤学会(CSCO)淋巴瘤专家委员会
徐兵
赵维莅
马军
赵海军
易红梅
查洁
Lymphoid Disease Group,Chinese Society of Hematology,Chinese Medical Association;Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Xu Bing;Zhao Weili;Ma Jun(不详;Department of Hematology,the First Affiliated Hospital of Xiamen University and Institute of Hematology,School of Medicine,Xiamen University,Xiamen Hematology Medical Quality Control Center,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy,Xiamen 361003,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,Chin;Harbin Institute of Hematology&Oncology,Harbin 1500010 Chhina)
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2024年第3期209-214,共6页
Chinese Journal of Hematology
关键词
淋巴瘤
大B细胞
纵隔
诊断
治疗
Lymphoma,Large B-Cell
Mediastinum
Diagnosis
Therapy
